Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is poised for long-term growth, with significant upside expected in 2027 and beyond, driven by strong top-line growth and a conservative posture towards reserves under new CFO Mario Ramos. With a focus on technology and AI initiatives, the company has an attractive growth proposition, with potential cross-selling, upselling, and new contract opportunities. While there are potential downside risks, our outlook remains positive, with a 2027 adjusted EBITDA estimate of $200 million and a target EV/EBITDA multiple of 10x, in line with the company's one-year average.

Bears say

Evolent Health is facing a challenging future due to its 2026 outlook, which is below Street expectations and more heavily weighted towards the second half of the year. This can primarily be attributed to the onboarding of $900 million in revenue from new Performance Suite contracts, as well as membership shifts within large existing customers. Additionally, the company's $15 million overpayment from a payor in the fourth quarter of 2025 will reverse in the first quarter of 2026, contributing to a decrease in projected EBITDA. These factors, combined with regulatory risks and potential challenges in maintaining profitability in at-risk contracts, make for a negative outlook on the company's stock performance.

Evolent Health (EVH) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 14 analysts, Evolent Health (EVH) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.